PRIMO 2024 | Broadening horizons in immuno-oncology: insights from PRIMO 2024

Ritu Salani, MD, MBA, from UCLA Health in Los Angeles, CA, reflects on the 2024 PRIMO meeting, emphasizing its value in providing a comprehensive overview of various organ sites beyond gynecological cancers. She highlights the cross-cutting nature of treatments such as PARP inhibitors, ADCs, immunotherapy, and targets like HER2 and TROP2, which demonstrate efficacy across different disease sites. Prof. Salani underscores the importance of considering tumor profiles rather than organ-specific characteristics in treatment decisions. Exposure to diverse treatment landscapes and disease sites at the meeting enriched her practice and provided valuable insights for future directions in oncology. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.